Summary
Alice Soragni is a translational cancer scientist and director of the Functional Precision Medicine Initiative at the University of Colorado Anschutz, focused on patient-derived 3D tumor organoid models for rare and treatment-resistant cancers. With eight years of experience bridging bench and clinic, she pioneers high-throughput mini-ring drug screening, bioprinted organoids, and deep-learning microscopy to reveal therapeutic vulnerabilities and de-risk drug development. Her platform is being evaluated in the PREMOST clinical trial, reflecting a rare track record of taking advanced functional assays toward clinical implementation. A professor of biomedical informatics and neurosurgery and former UCLA faculty, she also leads the Society for Functional Precision Medicine and founded a stealth venture to translate her lab’s technologies. Trained in Europe with a PhD from ETH Zürich and advanced degrees from the Università di Bologna, she combines rigorous quantitative methods with practical clinical impact. Colleagues describe her work as unusually integrative—melding organoid biology, automation, and AI—to accelerate personalized options for patients with few alternatives.
8 years of coding experience
14 years of employment as a software developer
Master of Science - MS, Master of Science - MS at Alma Mater Studiorum – Università di Bologna
Doctor of Philosophy - PhD, Doctor of Philosophy - PhD at ETH Zürich